Filed by Bristol-Myers Squibb Company
Pursuant to Rule 425 of the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934
Subject Company: Celgene Corporation
Commission File No.: 001-34912
Explantory Note: The following communications were made available by Bristol-Myers Squibb Company through its various social media accounts.
![](https://capedge.com/proxy/425/0001140361-19-000272/image0.jpg)
![](https://capedge.com/proxy/425/0001140361-19-000272/image1.jpg)
![](https://capedge.com/proxy/425/0001140361-19-000272/image2.jpg)
![](https://capedge.com/proxy/425/0001140361-19-000272/image3.jpg)
![](https://capedge.com/proxy/425/0001140361-19-000272/image4.jpg)
![](https://capedge.com/proxy/425/0001140361-19-000272/image5.jpg)
![](https://capedge.com/proxy/425/0001140361-19-000272/image6.jpg)
![](https://capedge.com/proxy/425/0001140361-19-000272/image7.jpg)